Boston Scientific Corp (NYSE:BSX) is one of Goldman Sachs top healthcare stocks. On March 4, TD Cowen reiterated that Boston Scientific Corp (NYSE:BSX) stock’s year-to-date decline appears overdone in the market. The stance follows a fireside chat with the company, whereby management affirmed confidence in achieving overall guidance.

The company also reiterated its positive outlook for its pulsed-field ablation and Watchman products. The company delivering on its guidance is expected to ease investor concern and trigger a stock recovery. Boston Scientific has already delivered 19.9% revenue growth over the past 12 months, affirming operational momentum despite recent headwinds.

Amid the positive outlook, TD Cowen has reiterated a Buy rating on Boston Scientific (BSX) with a $100 price target. The bullish outlook comes on the heels of the company delivering solid fourth-quarter and full-year 2025 earnings. Revenue in the quarter rose 15.9% year over year as adjusted earnings per share totaled $0.80, above the consensus estimate of $0.78 and guidance of $0.79.

Boston Scientific Corp. (NYSE:BSX) is a global medical technology leader that develops, manufactures, and markets less-invasive medical devices used in interventional specialties, including cardiology, peripheral interventions, electrophysiology, endoscopy, and urology. Their products, such as stents, pacemakers, and imaging systems, are used by healthcare professionals worldwide to diagnose and treat various diseases.

While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 11 Best Affordable Growth Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.